<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963196</url>
  </required_header>
  <id_info>
    <org_study_id>14503</org_study_id>
    <nct_id>NCT00963196</nct_id>
  </id_info>
  <brief_title>Study of Supplementation of Antidepressants With Fish Oil to Improve Time to Clinical Response</brief_title>
  <acronym>SADFAT</acronym>
  <official_title>Supplementation of Antidepressants With Fatty Acid Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a randomized controlled trial set in an outpatient clinic, involving&#xD;
      patients with major depressive disorder, who will be treated with antidepressant therapy,&#xD;
      which will be individually agreed upon by the subject and his or her physician. Patients will&#xD;
      be randomized to receive either placebo or fish oil capsules containing eicosapentaenoic acid&#xD;
      (EHA) and docosahexaenoic acid (DHA) in addition to their antidepressant medication. Subjects&#xD;
      will complete a brief dietary and exercise habits survey at the beginning of the trial to&#xD;
      take into account lifestyle factors that may be significant in symptom resolution. Their&#xD;
      progress will be monitored over a period of twelve weeks, with standardized rating scales&#xD;
      completed by subjects and treating physicians. At the end of the study, scores will be&#xD;
      compared between groups to look for differences in timing and degree of symptom improvement&#xD;
      to analyze whether improvement occurred faster in the group receiving essential fatty acids&#xD;
      (EFAs) than in the one receiving placebo. The primary hypothesis is that supplementation of&#xD;
      antidepressant therapy with omega-3 fatty acids will decrease the lag period between the&#xD;
      start of therapy and the time of clinically significant symptom improvement. A secondary&#xD;
      hypothesis is that the results of this study will be consistent with numerous previous&#xD;
      studies showing improvement in symptom control in major depressive disorder when&#xD;
      antidepressants are supplemented with omega-3 fatty acids.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    End of allotted time for subject recruiting.&#xD;
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in MADRS and PHQ-9 scores occurs in a shorter period of time in the intervention group versus the placebo group.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects in the intervention group experience greater reduction of scores in MADRS and PHQ-9 than the placebo group.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>One unsuccessful trial</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with one unsuccessful previous antidepressant trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>One successful trial</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with one previous successful antidepressant trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No previous trial</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with no prior antidepressant therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 fatty acid</intervention_name>
    <description>2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks</description>
    <arm_group_label>No previous trial</arm_group_label>
    <arm_group_label>One successful trial</arm_group_label>
    <arm_group_label>One unsuccessful trial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bovine gelatin capsules</intervention_name>
    <description>Bovine gelatin capsules that appear similar to active drug acting as placebo.</description>
    <arm_group_label>No previous trial</arm_group_label>
    <arm_group_label>One successful trial</arm_group_label>
    <arm_group_label>One unsuccessful trial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Major Depressive Disorder.&#xD;
&#xD;
          -  Allowed comorbidities: Dysthymia, Anxiety Disorders.&#xD;
&#xD;
          -  18 years old or older.&#xD;
&#xD;
          -  Males + Females.&#xD;
&#xD;
          -  English-speaking.&#xD;
&#xD;
          -  Women of reproductive age must be on adequate birth control, either oral&#xD;
             contraceptives or using condoms or other barrier methods with spermicidal agents.&#xD;
&#xD;
          -  Subjects may be undergoing psychotherapy, but must maintain current psychotherapy&#xD;
             status. Must not start therapy if not already in therapy. If in therapy, must have&#xD;
             received at least 6 sessions prior to entering the study.&#xD;
&#xD;
          -  Subjects may continue taking herbals or supplements during the study, but they may not&#xD;
             start any new herbals or supplements during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  2 or more failed trials of antidepressants (adequate dose and duration, and&#xD;
             documented).&#xD;
&#xD;
          -  Substance dependence in the past 6 months.&#xD;
&#xD;
          -  Current substance use or abuse (MJ, benzodiazepines, narcotics). If BZD use, patient&#xD;
             must be tapered off and wait 1 month before being included in the trial.&#xD;
&#xD;
          -  Psychosis.&#xD;
&#xD;
          -  Bipolar Affective Disorder Type I, II or NOS.&#xD;
&#xD;
          -  Pregnancy (current or planned).&#xD;
&#xD;
          -  Unstable medical illness (pt has to be stable for at least 3 months, and may be&#xD;
             excluded per investigator discretion).&#xD;
&#xD;
          -  Dementia.&#xD;
&#xD;
          -  Mental retardation.&#xD;
&#xD;
          -  Traumatic Brain Injury.&#xD;
&#xD;
          -  History of Stroke.&#xD;
&#xD;
          -  History of seizure disorder.&#xD;
&#xD;
          -  Electroconvulsive therapy within past 6 months.&#xD;
&#xD;
          -  If, at the investigator's discretion, it is suspected that the subject will likely not&#xD;
             comply with the study protocol.&#xD;
&#xD;
          -  Imminent risk for suicide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anita H Clayton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UVA Psychiatry Outpatient Clinic</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hallahan B, Garland MR. Essential fatty acids and mental health. Br J Psychiatry. 2005 Apr;186:275-7.</citation>
    <PMID>15802681</PMID>
  </reference>
  <reference>
    <citation>Hallahan B, Garland MR. Essential fatty acids and their role in the treatment of impulsivity disorders. Prostaglandins Leukot Essent Fatty Acids. 2004 Oct;71(4):211-6. Review.</citation>
    <PMID>15301790</PMID>
  </reference>
  <reference>
    <citation>Hibbeln JR. Fish consumption and major depression. Lancet. 1998 Apr 18;351(9110):1213.</citation>
    <PMID>9643729</PMID>
  </reference>
  <reference>
    <citation>Gesch CB, Hammond SM, Hampson SE, Eves A, Crowder MJ. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomised, placebo-controlled trial. Br J Psychiatry. 2002 Jul;181:22-8.</citation>
    <PMID>12091259</PMID>
  </reference>
  <reference>
    <citation>Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003 Jul 15;108(2):155-60. Epub 2003 Jun 23.</citation>
    <PMID>12821543</PMID>
  </reference>
  <reference>
    <citation>Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1999 May;56(5):407-12.</citation>
    <PMID>10232294</PMID>
  </reference>
  <reference>
    <citation>Tanskanen A, Hibbeln JR, Hintikka J, Haatainen K, Honkalampi K, Viinamäki H. Fish consumption, depression, and suicidality in a general population. Arch Gen Psychiatry. 2001 May;58(5):512-3.</citation>
    <PMID>11343534</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>August 20, 2009</study_first_submitted>
  <study_first_submitted_qc>August 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2009</study_first_posted>
  <last_update_submitted>June 2, 2010</last_update_submitted>
  <last_update_submitted_qc>June 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Anita Clayton MD</name_title>
    <organization>University of Virginia Department of Psychiatry and Neurobehavioral Sciences</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

